Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with a poor
prognosis and limited therapeutic options. To aid the development of novel immunological …

Hepatocellular carcinoma (HCC) has a poor prognosis with limited therapeutic options. We
propose that local immune responses in patients with HCC are held in check by tumor …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, with a
poor prognosis and limited therapeutic options. Therefore, the development of novel …

Aim We investigated whether tumor-specific CD8+ T-cell responses affect tumor-free
survival as well as the relationship between CD8+ T-cell responses against tumor …

Immunotherapy is being proposed to treat patients with hepatocellular carcinoma (HCC).
However, more detailed knowledge on tumor Ag expression and specific immune cells is …

Host antitumor immune responses may be different between hepatocellular carcinoma
(HCC) caused by metabolic disorders and HCC associated with hepatitis virus infection. In …

BACKGROUND & AIMS: Tumor and viral antigens are expressed by hepatocellular
carcinoma (HCC) in patients with chronic hepatitis B, but little is known about the …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with
limited therapeutic options. Since HCC has been shown to be immunogenic, T cell-based …

BACKGROUND/AIMS: The immune response to tumor-specific antigens is typically unable
to control the growth and spread of malignant cells. Accumulating evidence indicates that …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor
prognosis and one for which immunotherapy remains a viable option. Experimental tumor …